Immunocore Holdings plc
IMCR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 3.71 | -3.19 | 0.71 | -0.17 |
| FCF Yield | 1.42% | -0.07% | -2.38% | -13.44% |
| EV / EBITDA | -37.70 | -57.73 | -47.86 | -5.04 |
| Quality | ||||
| ROIC | -6.80% | -11.79% | -10.00% | -53.49% |
| Gross Margin | 96.61% | 99.58% | 96.33% | 100.00% |
| Cash Conversion Ratio | -0.51 | -0.07 | 0.94 | 0.79 |
| Growth | ||||
| Revenue 3-Year CAGR | 19.76% | 89.79% | 68.56% | 12.43% |
| Free Cash Flow Growth | 940.56% | 95.17% | 64.42% | -127.02% |
| Safety | ||||
| Net Debt / EBITDA | 0.60 | 6.94 | 8.37 | 1.41 |
| Interest Coverage | -2.99 | -11.57 | -7.91 | -31.33 |
| Efficiency | ||||
| Inventory Turnover | 1.54 | 0.23 | 7.65 | 0.00 |
| Cash Conversion Cycle | -732.79 | -4,590.34 | -804.07 | 335.40 |